Moderna Inc. has published the transcript of its fourth quarter 2025 earnings call, which took place on February 13, 2026. The event brought together key members of the company's leadership, including the Chief Executive Officer, Chief Financial Officer, President, and Head of Investor Relations, along with several analysts from major financial institutions. During the call, management reviewed Moderna's 2025 financial results and provided updates on business operations, clinical programs, and commercial outlook. The discussion addressed the company's ongoing focus on mRNA medicine and highlighted progress in oncology, rare disease, and infectious disease programs. "Our progress, clinical, commercial, operational, is dedicated to one mission, delivering the greatest possible impact to people through mRNA medicine," stated the CEO. The call also included insights on the implications of the flu RTF for the 2028 cash flow breakeven guidance and updates on the INT program in adjuvant melanoma, described as an important catalyst for the company. The full transcript can be accessed through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on February 13, 2026, and is solely responsible for the information contained therein.